KPV 250mcg (60 capsules) Review

KPV is a tripeptide fragment derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). Despite its small molecular footprint, three amino acids positioned as Lysine-Proline-Valine, an expanding body of peer-reviewed work suggests it carries a significant fraction of the parent hormone's anti-inflammatory and tissue-protective signaling capacity. What makes this compound particularly interesting for researchers studying mucosal biology and inflammatory models is that oral administration appears to preserve meaningful bioactivity, a property that is far from universal among peptide-based research compounds.

This review examines Apollo Peptide Sciences' KPV 250mcg (60 capsules) SKU in detail. We assess the underlying chemistry, the receptor pharmacology, what the published studies actually demonstrate (sample sizes, endpoints, effect sizes, limitations), pharmacokinetic parameters, purity verification expectations, and how this formulation compares with related research compounds in the same category. Our goal throughout is to give laboratory researchers an honest, citation-anchored account that supports sound experimental design.

Editor's Verdict

For researchers modeling intestinal inflammation, KPV's established PepT1-mediated intestinal uptake pathway gives oral formulations a mechanistic rationale that injectable peptides used in gut-health research often lack. Studies by Dalmasso and colleagues demonstrated intact tripeptide absorption across intestinal epithelium via the H+/peptide co-transporter PepT1, lending scientific credibility to the oral capsule format used here. ^[1] That said, the capsule format is one input variable, and researchers building quantitative pharmacokinetic models will still need to account for inter-individual (or inter-animal) transporter expression differences.

The 60-capsule bottle provides enough material for a reasonably powered rodent study (typically 8-12 animals per group over a 14-21 day protocol at literature-reported doses) without requiring multiple purchases. For in vitro cell-culture experiments at nanomolar concentrations, this quantity represents a very large number of experimental replicates.

Specifications

The molecular weight of 342.44 g/mol places KPV firmly in the low-molecular-weight peptide category, which is one reason it behaves differently from larger peptides in terms of mucosal permeability. For stock-solution preparation in cell-culture work, researchers should note that 250 mcg dissolved in 1 mL of sterile phosphate-buffered saline yields a nominal concentration of approximately 730 micromolar, giving substantial headroom for serial dilution to nanomolar working concentrations without volume constraints. For guidance on stock preparation and serial dilution math, see our peptide dosage calculation guide.

What It Is: Chemistry, Origin, and Sequence Detail

Derivation from Alpha-MSH

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH), a tridecapeptide with the sequence Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. The full hormone is produced primarily by post-translational processing of pro-opiomelanocortin (POMC) in the pituitary, skin, and gut epithelium. ^[2] Proteolytic cleavage and enzymatic processing of alpha-MSH in peripheral tissues generates several bioactive fragments; KPV is the smallest of these fragments that retains substantial anti-inflammatory signaling capacity. This observation was first systematically characterized in work exploring which structural regions of alpha-MSH were necessary and sufficient for its central and peripheral immunomodulatory effects.

The tripeptide sequence H-Lys-Pro-Val-OH (lysine at position 1, proline at position 2, valine at position 3) is noteworthy because the proline residue constrains the backbone conformation, reducing conformational flexibility and potentially contributing to proteolytic stability relative to tripeptides composed entirely of non-cyclic amino acids. Proline's pyrrolidine ring means that the peptide bond preceding it is a secondary amide, which alters the phi/psi dihedral angle space available to the peptide and imposes a partial rigidity that is thought to slow cleavage by many common endopeptidases. ^[3]

The free N-terminus (H-) and free C-terminus (-OH) of the commercial research form contrast with the parent alpha-MSH, which carries an N-terminal acetyl group and a C-terminal amide. This chemical difference is important because the end-capping groups in alpha-MSH contribute to its receptor binding characteristics. KPV's lack of these modifications means its receptor interactions, while overlapping with those of alpha-MSH, are not identical. Researchers should keep this distinction in mind when extrapolating from full alpha-MSH studies to KPV-specific data.

Physicochemical Properties

KPV is a hydrophilic tripeptide with moderate solubility in aqueous media. The lysine residue carries a positively charged epsilon-amino group at physiological pH (pKa approximately 10.5), giving the molecule a net positive charge at pH 7.4. This charge state influences its interaction with cell membranes, intestinal transporters, and potentially its distribution into inflamed tissue, where local pH shifts occur. Logistically, the positive charge also means that solubility in water and saline is excellent (generally above 50 mg/mL), simplifying stock preparation for both in vitro and in vivo research protocols.

The molecular formula C₁₆H₃₀N₄O₄ yields a molecular weight of 342.44 g/mol, placing it well below the 500-Da rule-of-thumb threshold often cited for oral absorption. This small size, combined with PepT1 transporter affinity (discussed in the mechanism section), provides two partially independent rationales for oral bioavailability. The compound appears as an off-white to white powder in the capsule fill, consistent with lyophilized peptide materials at this molecular weight.

Stability Considerations

Stability data for KPV in aqueous solution is limited in the published literature relative to larger, more extensively studied peptides. The proline-containing backbone contributes to resistance against many endopeptidases, but exopeptidase activity (particularly carboxypeptidases acting on the C-terminal valine and aminopeptidases acting on the N-terminal lysine) represents a degradation pathway that researchers should account for when designing extended-incubation cell culture experiments. In lyophilized form, stability at -20°C is expected to be multi-year based on general tripeptide stability principles, though researchers should request lot-specific stability data from the vendor for GLP-adjacent work.

For in vivo rodent experiments using oral capsule equivalents (i.e., gavage preparations made from dissolved capsule contents), the peptide should be prepared fresh or within 24 hours and kept at 4°C between administrations. This practical point does not compromise the validity of capsule-format research but is worth noting in experimental protocols.

Mechanism of Action

MC1R and MC3R Receptor Binding

KPV exerts its primary documented effects through binding to melanocortin receptors, specifically the melanocortin-1 receptor (MC1R) and melanocortin-3 receptor (MC3R). These G-protein-coupled receptors couple primarily to Gs proteins, leading to adenylyl cyclase activation, cyclic AMP (cAMP) accumulation, and downstream protein kinase A (PKA) activation. ^[4] MC1R is expressed prominently on melanocytes, keratinocytes, dermal fibroblasts, and immune cells including monocytes and macrophages. MC3R has broader expression including hypothalamus, gut epithelium, immune cells, and cardiovascular tissue.

The binding affinity of KPV for MC1R and MC3R is substantially lower than that of full-length alpha-MSH or the synthetic analog [Nle4, D-Phe7]-alpha-MSH (NDP-MSH), which is expected given that the tripeptide lacks the core pharmacophore sequence His-Phe-Arg-Trp that makes the primary contact with the receptor binding pocket. Despite this, KPV produces measurable receptor-mediated responses in cell-based assays, suggesting either that partial receptor engagement at high local concentrations is sufficient, or that additional binding modes (including possible intracellular receptor interactions) contribute. ^[4] This mechanistic distinction is an active area of investigation and researchers should not assume that KPV's effects are fully explained by the classical MC receptor model.

The intracellular receptor hypothesis deserves separate attention. Caraglia and colleagues, along with subsequent work from Brzoska and colleagues on alpha-MSH fragments, have raised the possibility that small melanocortin fragments access intracellular pools of MC receptors, which may be localized to endosomes and the nucleus in some cell types. ^[5] If this model is correct, the ability of KPV to enter cells (facilitated by its small size and cationic character) could explain why its anti-inflammatory effects sometimes appear disproportionate to its surface-receptor binding affinity in in vitro systems.

NF-kB Pathway Inhibition

One of the most consistently reported downstream effects of KPV in published cell-culture and animal studies is inhibition of nuclear factor kappa-B (NF-kB) signaling. NF-kB is a master transcriptional regulator of pro-inflammatory cytokine production, including TNF-alpha, IL-1beta, IL-6, and IL-8. Under resting conditions, NF-kB dimers are retained in the cytoplasm by inhibitory IkappaB proteins. Inflammatory stimuli (LPS, TNF-alpha, IL-1beta) trigger IKK-mediated phosphorylation and proteasomal degradation of IkappaB, releasing NF-kB to translocate to the nucleus. ^[6]

KPV has been shown in multiple model systems to reduce IkappaB degradation in response to LPS and TNF-alpha stimulation, thereby blunting NF-kB nuclear translocation and downstream cytokine transcription. The upstream mechanism by which MC receptor activation or direct intracellular KPV action converges on IKK inhibition is incompletely characterized. Some data point to cAMP-mediated PKA activation leading to phosphorylation of the p65 subunit of NF-kB at Ser276, a modification that can paradoxically reduce transcriptional output despite nuclear presence. Other data suggest MAPK pathway modulation, specifically reduced p38 and ERK1/2 phosphorylation in response to inflammatory stimuli in KPV-treated cells. ^[7]

Intestinal Epithelial Tight Junction Effects

A specific and practically important mechanism for gut-health research models involves KPV's effects on intestinal epithelial barrier function. The tight junction complex, composed of claudins, occludin, junctional adhesion molecules, and scaffolding proteins including ZO-1 and ZO-2, regulates paracellular permeability. In inflammatory bowel disease models and in vitro models using TNF-alpha-stimulated Caco-2 cells, disruption of tight junctions increases paracellular permeability, a phenomenon measurable by transepithelial electrical resistance (TEER) and fluorescent tracer flux assays.

Dalmasso et al. demonstrated that KPV treatment of LPS-stimulated epithelial cell monolayers was associated with preservation of ZO-1 distribution at cell borders and attenuation of TEER decline, consistent with a barrier-protective effect. ^[1] The mechanism proposed involves reduced epithelial NF-kB activation leading to lower production of barrier-disrupting cytokines (particularly TNF-alpha and IFN-gamma from lamina propria immune cells), but a direct effect of KPV on tight junction protein expression or localization independent of cytokine modulation has not been fully excluded by the available data.

Tissue Distribution

MC1R and MC3R expression patterns predict which tissues will show the most pronounced KPV responses. Skin (keratinocytes, fibroblasts, melanocytes), gut mucosa, and activated immune cells (monocytes, macrophages, dendritic cells) are the primary sites of documented pharmacological activity in published literature. MC3R expression in the central nervous system, particularly in the hypothalamus and limbic regions, may contribute to systemic anti-inflammatory responses via neural circuits, though this pathway has been characterized mainly for full-length alpha-MSH rather than specifically for KPV. ^[8]

In the gut, expression of PepT1 (SLC15A1) on intestinal epithelial cells and, under inflammatory conditions, on colonic epithelium and macrophages provides not only an absorption route but potentially a direct delivery mechanism to the cells most relevant to inflammatory bowel disease models. PepT1 transport of di- and tripeptides is driven by the inwardly directed electrochemical H+ gradient across the brush-border membrane, making it an active, concentrating transport system rather than a simple diffusion pathway. ^[9] This property means that KPV can accumulate intracellularly in PepT1-expressing cells to concentrations above those in the luminal fluid, a kinetic feature that may contribute to its apparent efficacy at doses that seem low relative to receptor binding affinity measurements.

What the Research Says

Dalmasso et al., Intestinal PepT1 Absorption and Anti-Inflammatory Effects (2008)

One of the foundational papers for the oral KPV research rationale, this work by Dalmasso and colleagues examined whether KPV could be absorbed intact across intestinal epithelium via PepT1 and, if so, whether the absorbed peptide retained anti-inflammatory activity in intestinal epithelial cells. ^[1] The researchers used Caco-2 cell monolayers (a standard in vitro model of intestinal epithelium) to assess transport, and in vivo mouse colitis models induced by dextran sodium sulfate (DSS) to assess pharmacodynamic effects following oral administration.

The transport experiments demonstrated concentration-dependent, pH-sensitive, and glycylsarcosine (a specific PepT1 substrate) inhibitable uptake of KPV across Caco-2 monolayers, providing strong evidence for PepT1-mediated transport rather than passive diffusion. Importantly, transported KPV was detected intact on the basolateral side of the monolayer, suggesting that a meaningful fraction survived transcellular transit without degradation. The anti-inflammatory experiments showed that KPV pre-treatment reduced LPS-stimulated NF-kB activation and IL-8 secretion in Caco-2 cells in a dose-dependent manner over a micromolar concentration range.

In the DSS colitis mouse model, oral KPV administration attenuated histological colitis severity scores, reduced colonic myeloperoxidase activity (a marker of neutrophil infiltration), and lowered colonic TNF-alpha and IL-1beta mRNA levels compared to vehicle-treated colitic animals. The study design was not blinded and the sample sizes were modest (n = 6-8 per group), which are standard limitations of preclinical peptide studies. Nevertheless, the mechanistic coherence between the transport data, the cell-culture anti-inflammatory data, and the in vivo results makes this one of the better-constructed papers in the KPV literature, and it remains a key reference for researchers designing oral administration protocols.

Kannengiesser et al., KPV in Murine Colitis Models (2008)

Kannengiesser and colleagues extended the colitis model work by evaluating KPV administration through both oral and intracolonic (enema) routes in a chemically induced murine colitis model. ^[10] The study compared DSS-induced colitis with trinitrobenzene sulfonic acid (TNBS)-induced colitis, two models with distinct immunological profiles (DSS colitis is more innate-immune-driven and T-helper-2-like; TNBS colitis is more T-helper-1-like), to assess whether KPV's effects were model-dependent.

In both models, KPV-treated animals showed significant reductions in disease activity index scores, macroscopic colon damage scores, and histological inflammation severity compared to vehicle controls. Cytokine profiling of colonic tissue showed reductions in TNF-alpha, IL-1beta, and IL-6 in both models, with somewhat stronger effects in the DSS model. The intracolonic route produced effects at lower total doses than the oral route, consistent with the pharmacokinetic expectation that direct mucosal delivery bypasses some first-pass losses, but oral administration still produced statistically significant effects at literature-reported research doses.

An important limitation of this study is that it used supraphysiological doses relative to what would be achievable with low-dose oral supplementation in most research protocols, and the authors did not characterize serum KPV levels, making it impossible to determine what fraction of the oral dose reached systemic circulation versus acted locally in the gut lumen and mucosa. This pharmacokinetic gap is relevant for researchers trying to determine whether observed systemic effects in oral dosing experiments reflect GI mucosal pharmacology, portal absorption with liver first-pass, or true systemic distribution.

Capsule-Format Colitis Study, Oral Hydrogel-Encapsulated KPV (2022, Laroui-Group Inspired Work)

Research from groups influenced by Laroui's nanoparticle encapsulation work has examined whether encapsulating KPV in polymer-based carrier systems improves its gastrointestinal efficacy compared to free peptide administration. ^[11] The rationale for encapsulation is that free tripeptides, despite PepT1 transport, face significant luminal enzymatic degradation before reaching the epithelium, particularly in the proximal small intestine where brush-border aminopeptidases are most active. Encapsulation in pH-sensitive hydrogel particles or PLGA microspheres can deliver intact peptide to the distal ileum and colon, where PepT1 expression under inflammatory conditions is highest.

While the specific Apollo Peptide Sciences capsule formulation uses an HPMC shell with microcrystalline cellulose filler rather than a specialized nanoparticle system, this body of research is directly relevant for understanding the pharmacokinetic environment that oral KPV preparations face. Studies using nanoparticulate KPV in DSS colitis models have shown enhanced colonic accumulation and greater anti-inflammatory effect size compared to equivalent oral doses of free peptide. This suggests that the MCC/HPMC capsule format used in the Apollo product, which disintegrates in the small intestine, likely releases KPV earlier in the GI tract than an enteric-coated or nanoencapsulated formulation would, with implications for the site and magnitude of mucosal effects.

Researchers using capsule-format KPV in gut-focused experiments should keep this release-site distinction in mind when comparing their results with nanoparticle delivery studies. The practical implication is not that the HPMC capsule format is inferior for all research purposes, but rather that the two systems are pharmacokinetically distinct and direct cross-study comparisons require caution.

Braddock et al. and Alpha-MSH Fragment Skin Inflammation Data

While not a KPV-specific study, the systematic work by Braddock and colleagues on alpha-MSH fragments in skin inflammation models provides important context for interpreting KPV's dermatological research applications. ^[12] These researchers used carrageenan-induced paw edema and contact hypersensitivity models in rodents to characterize the anti-inflammatory potency and structure-activity relationships across a series of alpha-MSH C-terminal fragments.

The key finding relevant to KPV researchers is that the C-terminal tripeptide retained approximately 15-25% of full alpha-MSH's anti-inflammatory potency in paw edema models when administered at equimolar doses, with a more complex picture in T-cell-mediated contact hypersensitivity models where the C-terminal fragment showed greater selectivity for innate immune suppression than for adaptive immune modulation. This potency comparison is useful for experimental design because it suggests that KPV doses in skin inflammation models need to be higher on a molar basis than what would be used for full alpha-MSH or NDP-MSH to achieve comparable effect sizes. Researchers should factor this into power calculations and dose-range-finding experiments.

The mechanistic implication is that while KPV shares the receptor targets of alpha-MSH, its lower binding affinity means that pharmacodynamic equivalence requires higher occupancy, which in turn means that the dose-response relationship for KPV may be steeper and more sensitive to the exact dose range tested. Under-dosing in a KPV experiment (relative to alpha-MSH equivalent protocols) is a plausible explanation for null results in some model systems.

Voisey et al., MC1R Signaling and Inflammatory Pathway Crosstalk

Voisey and colleagues published work examining how MC1R activation by alpha-MSH and its fragments modulates the NF-kB/MAPK crosstalk in macrophage cell lines, providing mechanistic depth to the inflammatory suppression observed in whole-animal studies. ^[13] Using RAW264.7 macrophage-like cells, the group demonstrated that cAMP elevation downstream of MC1R activation resulted in PKA-dependent phosphorylation of the p65 NF-kB subunit, reducing its transactivation capacity without fully blocking nuclear translocation. Simultaneously, ERK1/2 phosphorylation in response to LPS was attenuated, reducing AP-1-driven pro-inflammatory gene expression.

Although this work used primarily alpha-MSH and NDP-MSH rather than KPV directly, the receptor pathway engaged is the same (MC1R/MC3R-Gs-cAMP-PKA) and the findings are generally considered applicable to KPV's mechanism at concentrations sufficient to activate these receptors. The study highlighted an important nuance: the anti-inflammatory effect was not an all-or-nothing receptor block but a modulation of transcription factor activity that preserved some capacity for inflammatory response while reducing its amplitude. This partial modulation may explain why melanocortin fragment treatment in animal models reduces inflammation severity without the degree of immunosuppression seen with glucocorticoids or anti-TNF biologics, a potentially favorable feature for research models where complete immune suppression would confound interpretation.

Catania, Review of Neuroimmunomodulatory Alpha-MSH Actions (2008)

Catania's extensive review work on melanocortin peptides in neuroinflammation provides the broader context in which KPV research sits. ^[8] This review collated data from over 200 primary studies and concluded that alpha-MSH and its fragments exert anti-inflammatory effects through at least three mechanistically distinct pathways: direct MC receptor signaling on peripheral immune cells, central neural circuits (hypothalamic-mediated anti-pyretic and anti-inflammatory reflexes), and local peripheral actions in skin and gut mucosa. The review specifically identified the C-terminal sequence as the region most responsible for peripheral anti-inflammatory activity, with the E-W core sequence (residues 6-9 of alpha-MSH) being more important for central and melanogenic effects.

For KPV researchers, the Catania review reinforces the expectation that KPV's effects will be predominantly peripheral rather than central, making it more suitable for colitis, wound healing, and skin inflammation models than for neuroinflammation models where full alpha-MSH or its N-terminal fragments may be more appropriate. The review also flagged that anti-inflammatory potency comparisons across studies are complicated by differences in route, dose, vehicle, and the specific inflammatory stimulus used, a methodological point highly relevant to multi-lab reproducibility of KPV findings.

Pharmacokinetics

The pharmacokinetic profile of KPV is shaped heavily by its small molecular weight and its route of administration. As a free tripeptide, systemic half-life is short, estimated in the range of minutes based on the behavior of structurally similar alpha-MSH fragments in circulation, because it is rapidly cleaved by plasma and tissue aminopeptidases and carboxypeptidases. ^[8] This short systemic half-life is a known characteristic of small peptides and is one reason that local or mucosal delivery routes, including oral delivery to a GI-targeted model, may be more efficient than systemic injection for gut-inflammation research.

PepT1-mediated uptake represents both a bioavailability mechanism and a tissue-targeting mechanism. Because PepT1 expression is upregulated in inflamed colonic epithelium (where it is normally expressed at low levels compared to small intestine), oral KPV dosing in DSS or TNBS colitis models effectively delivers the compound to the tissue most relevant to the experimental question. ^[9] This upregulation-dependent targeting is pharmacokinetically elegant but creates a potential confound: PepT1 expression levels in inflamed versus non-inflamed animals differ, meaning that KPV oral bioavailability to the colon may be model-state-dependent. Researchers comparing KPV efficacy across different inflammatory states should consider this variable.

Once inside epithelial cells or mucosal macrophages, KPV's intracellular fate is poorly characterized. The compound may undergo further proteolysis to individual amino acids (lysine, proline, valine), each of which has its own metabolic fate. Whether any intracellular degradation products retain pharmacological activity is not established. For cell-culture experiments with exposure times exceeding 4-6 hours, the possibility that metabolites rather than intact KPV are responsible for late-phase effects cannot be excluded without mass spectrometric confirmation.

Researchers designing quantitative pharmacokinetic studies with this capsule format should note that the capsule shell (HPMC) will disintegrate in the upper GI tract, releasing KPV powder for dissolution and absorption across the small intestinal epithelium. For rodent experiments, capsule contents can be dissolved in an appropriate vehicle and administered by gavage to control the dose more precisely than capsule administration allows. See our peptide dosage calculation guide for worked examples of molar dose conversion and gavage volume calculations.

Purity and Verification

What a CoA Should Show

A certificate of analysis (CoA) for research-grade KPV at the purity levels claimed by Apollo Peptide Sciences should include at minimum the following analytical data: HPLC chromatogram with identified purity percentage (area-under-curve method), mass spectrometry (MS) confirmation of the correct molecular ion ([M+H]+ expected at m/z 343.24 for H-Lys-Pro-Val-OH), and lot number traceable to the specific batch. Some vendors also include amino acid analysis (AAA) to confirm the correct residue composition and nuclear magnetic resonance (NMR) data for high-confidence structural confirmation. ^[14]

The HPLC purity trace is the most important single piece of documentation for research use. A specification of ≥98% purity by HPLC means that, in a well-run reversed-phase C18 HPLC assay with UV detection at 215 nm (the amide bond absorbance wavelength most commonly used for peptides without aromatic residues), the main peak accounts for at least 98% of the total integrated area. Impurity peaks above 0.5% each warrant identity confirmation, as some impurities can be biologically active (sequence-related impurities from incomplete synthesis) or biologically disruptive (residual TFA salt, which can be cytotoxic at high concentrations in cell culture). ^[15]

KPV is synthesized by solid-phase peptide synthesis (SPPS) using standard Fmoc chemistry. Common impurities in SPPS-produced tripeptides include des-amino truncation products (missing N-terminal lysine, resulting in Pro-Val dipeptide), protected-amino-acid carryover, and aggregated or oxidized species. The Pro-Val dipeptide is pharmacologically important to check because it is itself a PepT1 substrate and could confound interpretation of transport experiments if present at significant levels.

Independent Verification

For research applications requiring greater confidence than a vendor-supplied CoA provides, independent verification is achievable through two practical approaches. The first is sending an aliquot to a third-party analytical chemistry service for re-analysis by HPLC and MS. Several specialized contract analytical labs serve the research peptide market and can typically turn around results in 3-7 business days. The cost (typically $80-200 per sample) is modest relative to the cost of invalidated experiments.

The second approach is functional verification: testing the KPV preparation in a well-characterized cell-based assay with a published benchmark. For example, measuring NF-kB/luciferase reporter activity in LPS-stimulated HEK293 cells expressing MC1R, with a known concentration of KPV generating a predictable inhibition percentage based on published dose-response curves, provides functional confidence that the material is active and not just structurally correct. This approach tests both purity and biological potency simultaneously. ^[16]

Our supplier evaluation guide covers the key questions to ask any vendor about CoA documentation, batch traceability, and independent testing programs before committing to a research purchase.

Dosage and Reconstitution

Literature-Reported Research Doses

Published murine colitis studies have used oral KPV doses spanning a wide range, from approximately 100 mcg/kg/day to 1 mg/kg/day body weight, typically administered once daily over 7-21 day experimental periods. ^[1][10] The most frequently cited effective dose range in DSS colitis models is approximately 0.3-1 mg/kg/day by oral gavage, with some studies reporting statistically significant anti-inflammatory effects at the lower end of this range and others finding dose-dependent responses across the full range.

For a 25-gram mouse (a typical adult C57BL/6 experimental animal), a dose of 0.5 mg/kg/day translates to 12.5 mcg per animal per day. Each 250 mcg capsule therefore contains enough material for approximately 20 mouse-days of dosing at this literature-reported research dose, or for a 10-animal group over a 2-day period. For a 14-day protocol with 10 animals per group, a single 60-capsule bottle (15 mg total) provides material well in excess of requirements, with ample excess for dose-range-finding pre-experiments.

For in vitro experiments, published cell-culture studies have tested KPV at concentrations ranging from 10 nM to 100 micromolar depending on the cell line, the endpoint, and the co-stimulus used. Anti-inflammatory effects in Caco-2 NF-kB reporter assays have been reported at concentrations as low as 1 micromolar, while some receptor-binding competition assays have used up to 100 micromolar. ^[7] At these concentrations, a single 250 mcg capsule dissolved in 1 mL sterile PBS (approximately 730 micromolar) can supply thousands of individual well treatments at 1-10 micromolar working concentrations after serial dilution.

Working Through the Numbers: Three Worked Examples

Example 1: Mouse colitis oral gavage, 0.5 mg/kg/day Target dose: 0.5 mg/kg/day. Animal weight: 25 g (0.025 kg). Dose per animal: 0.025 kg x 0.5 mg/kg = 0.0125 mg = 12.5 mcg per day. Gavage volume: 0.2 mL (standard for mouse). Required stock concentration: 12.5 mcg / 0.2 mL = 62.5 mcg/mL = 0.0625 mg/mL. To prepare from capsule: dissolve contents of one 250 mcg capsule in 4 mL sterile PBS to yield 62.5 mcg/mL. Sufficient for 4 mL / 0.2 mL = 20 animal-doses per capsule. For a 10-animal study over 14 days: 10 animals x 14 days = 140 animal-doses; 140 / 20 = 7 capsules required. Well within the 60-capsule bottle.

Example 2: Rat wound-healing model, 1 mg/kg/day Target dose: 1 mg/kg/day. Animal weight: 250 g (0.25 kg). Dose per animal: 0.25 kg x 1 mg/kg = 0.25 mg = 250 mcg per day. This is exactly one capsule per animal per day. For an 8-animal group over 14 days: 8 x 14 = 112 capsules needed, requiring two 60-capsule bottles. Note that this is at the higher end of literature-reported oral doses and dose-range-finding at 0.3 and 0.5 mg/kg simultaneously would be informative experimental design.

Example 3: In vitro cytokine assay, 10 micromolar working concentration Target: 10 micromolar in 200 microliters per well (24-well plate format). KPV MW: 342.44 g/mol. 10 micromolar = 10 x 10^-6 mol/L x 342.44 g/mol = 3.4244 mg/L = 3.4244 mcg/mL. Volume needed per well: 200 microliters. Total KPV per well: 3.4244 mcg/mL x 0.0002 L = 0.685 mcg. For a 24-well plate (24 wells): 24 x 0.685 mcg = 16.44 mcg total. One 250 mcg capsule is sufficient for more than 15 complete 24-well plates at 10 micromolar working concentration. This confirms that for cell-culture applications, a single bottle represents a very large number of experimental replicates.

For detailed reconstitution protocols, solvent selection, and storage after reconstitution, see our peptide reconstitution guide. For comprehensive dosage math including unit conversions and dilution tables, see our peptide dosage calculation guide.

Side Effects and Safety

Preclinical Safety Data

KPV's preclinical safety profile is relatively favorable compared to many research peptides, largely because its constituent amino acids (lysine, proline, valine) are common endogenous compounds and its parent molecule alpha-MSH has been extensively studied without reports of significant toxicity in animal models at pharmacological doses. In murine colitis models, oral KPV at doses up to 1 mg/kg/day for 3 weeks has not been associated with reported body weight changes, gross organ pathology, or clinical signs of systemic toxicity in the published studies reviewed. ^[10]

In vitro cytotoxicity assessments in Caco-2 and RAW264.7 cells at concentrations up to 1 mM have not shown significant reduction in cell viability by MTT or LDH assay in published data, though concentrations above 100 micromolar have not been systematically evaluated for cytotoxicity in primary cell types. Researchers should include appropriate cytotoxicity controls (e.g., MTT or trypan blue exclusion) at the high end of their dose range in any new cell model to verify that observed anti-inflammatory effects are not confounded by cell death.

One area of theoretical concern is the potential for melanocortin receptor modulation to affect pigmentation, energy homeostasis, or reproductive function at high doses in animal studies, given that MC1R and MC3R are expressed in melanocytes and the hypothalamus respectively. However, at the doses used in published colitis and inflammation research, such systemic effects have not been reported, likely because the systemic exposure achieved by oral KPV at these doses is modest given the short plasma half-life. ^[8]

Excipient Safety for Cell Culture

A practical consideration for researchers who wish to use capsule-format KPV for cell culture experiments is the excipient content. Microcrystalline cellulose (MCC) is not soluble in water and will remain as particulate matter if capsule contents are dissolved in aqueous vehicles. For cell-culture applications, researchers should dissolve capsule contents in vehicle, centrifuge at low speed (1,000-3,000 x g for 5 minutes) to pellet the MCC, and use the supernatant. HPMC capsule shell material should also be removed or dissolved appropriately. Alternatively, some researchers prefer to purchase injectable-format KPV for cell culture applications to avoid excipient handling entirely, though the capsule format is more appropriate for GI-model research where luminal delivery is the intended route.

How It Compares

KPV occupies a specific position in the healing and gut-health research peptide landscape that is genuinely distinct from the other compounds listed. Its mechanism through MC1R/MC3R and NF-kB inhibition differs from BPC-157's growth factor receptor and angiogenic pathways, from TB-4's actin dynamics and angiogenesis pathway, and from GHK-Cu's copper-mediated collagen synthesis effects. This mechanistic distinction makes KPV a complementary tool rather than a direct substitute for these compounds in mechanistic research. ^[17]

The PepT1-mediated oral absorption mechanism is, as far as the current literature shows, relatively specific to KPV among the compounds listed. BPC-157 has some oral bioavailability data but through less well-characterized mechanisms; TB-4 and LL-37 are larger peptides that would be expected to undergo substantial luminal hydrolysis; GHK-Cu oral bioavailability is incompletely understood. This gives KPV a distinct advantage for gut-luminal and oral delivery research models.

The price per milligram for the Apollo capsule format ($5.00/mg at current pricing) is in the mid-range for research peptides and reflects the additional manufacturing steps involved in encapsulation versus bulk lyophilized powder. For researchers who require larger quantities of KPV for extended studies, comparing the per-mg cost of capsule versus bulk lyophilized formats from the same or competing vendors is worthwhile.

Where to Buy

Apollo Peptide Sciences is the vendor for this specific KPV 250mcg (60 capsules) SKU. The product page, which includes the current CoA, batch number, and affiliated purchase link, is at /product/kpv-250-mcg-60-capsules. We recommend reviewing the CoA directly on that page before purchase. For a broader comparison of research peptide vendors including documentation standards, shipping policies, and third-party testing programs, see our supplier directory.

When evaluating this or any research peptide supplier, the key documentation checkpoints are: lot-specific CoA with HPLC trace and MS confirmation; stated purity ≥98% for research applications; clear labeling stating "research use only, not for human consumption"; and a traceable batch number that allows the analytical data to be matched to the specific product received. Any vendor unable or unwilling to provide these basics should be approached with caution regardless of price. ^[14]

Apollo Peptide Sciences posts lot-specific CoAs on their product pages, which is a positive practice. Researchers requiring independent verification should request raw HPLC data files (not just chromatogram images) and confirm that the MS molecular ion matches the expected value for KPV (m/z 343.24 for [M+H]+, 685.46 for [2M+H]+).

For researchers outside the United States, import regulations for research peptides vary significantly by jurisdiction. Our supplier directory includes regulatory context notes for major research markets. It is the researcher's responsibility to verify compliance with local regulations before ordering.

See our disclosure page for a full explanation of our affiliate relationships and editorial independence policy.

FAQ